The 3 Biggest And Best Obesity-Drug Stocks To Buy In 2017

Although several obesity drugs are now on the market, they haven’t caught on nearly as much as biopharmaceutical companies had hoped they would. Investors looking to buy obesity-drug stocks are better off finding companies that also have other products either on the market or in development.

Eisai, Novo Nordisk, and Roche Holding Ltd. fit that description well. Each of these companies markets obesity drugs, but each also sells a broad array of other products with multiple pipeline candidates potentially on the way. Here’s why Eisai, Novo Nordisk, and Roche rank as the three best obesity-drug stocks to buy in 2017.

MORE ON THIS TOPIC